સ્તન કેન્સર
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
ક્યાં જવું
આ trial માટે India માં 10 hospitals દર્દીઓ લઈ રહ્યા છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Ca…
Sponsor: Pfizer
NCT07062965 on ClinicalTrials.gov
છેલ્લે 19 Oct 2026 એ registry માં અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું